EADV I European Academy of Dermatology and Venereology
EADV 2025

EADV 2025: Psoriasis Treatment and Work Productivity Outcomes
/ Kåre Steinar Tveit
EADV 2025: Expanding the Therapeutic Role of Botulinum Toxin in Dermatology
/ Oliver Philip Kreyden
EADV 2025: Advancing Treatment Frontiers in Hidradenitis Suppurativa
/ Thrasyvoulos Tzellos
Diagnostic Challenges for Immunobullous Disorders in Elderly Patients in Lagos
/ Viola Ikebudu Adaeze
Non-Medical Switches of Biosimilar in Psoriasis Treatment Appears Safe
/ Christopher Willy Schwarz
High-Intensity Focused Ultrasound Reduced/Eliminated Tumors in 76% of Patients with Cutaneous Neurofibromas
/ Katrine Elisabeth Karmisholt
EADV 2022
EADV 2021
EADV 2021
The risk of infections in psoriasis patients treated with biologics during the COVID-19 pandemic
/ Lara van der Schoot / Juul van den Reek
Psoriasis has significant negative impact on quality of life
/ Dimitrios Loannides
New research on impact of COVID-19 on psoriasis patients
/ BestPractice Nordic
Danish researchers identify link between genital warts and immune system
/ BestPractice Nordic